nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—ALK—brain cancer	0.361	0.69	CbGaD
Bosutinib—EGFR—brain cancer	0.162	0.31	CbGaD
Bosutinib—Gastrointestinal toxicity—Lomustine—brain cancer	0.00974	0.0928	CcSEcCtD
Bosutinib—Gastrointestinal toxicity—Carmustine—brain cancer	0.00387	0.0369	CcSEcCtD
Bosutinib—Myelosuppression—Lomustine—brain cancer	0.00341	0.0325	CcSEcCtD
Bosutinib—Gastrointestinal toxicity—Etoposide—brain cancer	0.00299	0.0285	CcSEcCtD
Bosutinib—Pericarditis—Procarbazine—brain cancer	0.00235	0.0224	CcSEcCtD
Bosutinib—Hepatotoxicity—Lomustine—brain cancer	0.00207	0.0197	CcSEcCtD
Bosutinib—Febrile neutropenia—Procarbazine—brain cancer	0.00169	0.0161	CcSEcCtD
Bosutinib—Myelosuppression—Hydroxyurea—brain cancer	0.00168	0.016	CcSEcCtD
Bosutinib—Traumatic liver injury—Temozolomide—brain cancer	0.00165	0.0157	CcSEcCtD
Bosutinib—STK24—Teniposide—Etoposide—brain cancer	0.00138	0.382	CbGdCrCtD
Bosutinib—Myelosuppression—Carmustine—brain cancer	0.00135	0.0129	CcSEcCtD
Bosutinib—Pleural effusion—Procarbazine—brain cancer	0.00133	0.0126	CcSEcCtD
Bosutinib—Myelosuppression—Temozolomide—brain cancer	0.00131	0.0125	CcSEcCtD
Bosutinib—Febrile neutropenia—Hydroxyurea—brain cancer	0.00131	0.0124	CcSEcCtD
Bosutinib—Vandetanib—VEGFA—brain cancer	0.00118	0.296	CrCbGaD
Bosutinib—Febrile neutropenia—Carmustine—brain cancer	0.00106	0.0101	CcSEcCtD
Bosutinib—Myelosuppression—Etoposide—brain cancer	0.00105	0.00998	CcSEcCtD
Bosutinib—Febrile neutropenia—Temozolomide—brain cancer	0.00102	0.00972	CcSEcCtD
Bosutinib—Hepatotoxicity—Hydroxyurea—brain cancer	0.00102	0.0097	CcSEcCtD
Bosutinib—Vandetanib—EGFR—brain cancer	0.000997	0.25	CrCbGaD
Bosutinib—Pancytopenia—Lomustine—brain cancer	0.000953	0.00908	CcSEcCtD
Bosutinib—Gefitinib—EGFR—brain cancer	0.000947	0.237	CrCbGaD
Bosutinib—CASK—Teniposide—Etoposide—brain cancer	0.000888	0.246	CbGdCrCtD
Bosutinib—Renal failure—Lomustine—brain cancer	0.000879	0.00838	CcSEcCtD
Bosutinib—Gefitinib—CYP2C9—brain cancer	0.000863	0.216	CrCbGaD
Bosutinib—Hepatic function abnormal—Procarbazine—brain cancer	0.000843	0.00804	CcSEcCtD
Bosutinib—Hepatotoxicity—Carmustine—brain cancer	0.000822	0.00784	CcSEcCtD
Bosutinib—Febrile neutropenia—Etoposide—brain cancer	0.000816	0.00778	CcSEcCtD
Bosutinib—Hepatotoxicity—Temozolomide—brain cancer	0.000795	0.00757	CcSEcCtD
Bosutinib—Gamma-glutamyltransferase increased—Temozolomide—brain cancer	0.000746	0.00711	CcSEcCtD
Bosutinib—Liver injury—Temozolomide—brain cancer	0.000729	0.00695	CcSEcCtD
Bosutinib—Rash maculo-papular—Hydroxyurea—brain cancer	0.000714	0.00681	CcSEcCtD
Bosutinib—Infection—Carboplatin—brain cancer	0.000648	0.00617	CcSEcCtD
Bosutinib—Hepatotoxicity—Etoposide—brain cancer	0.000636	0.00606	CcSEcCtD
Bosutinib—Leukopenia—Lomustine—brain cancer	0.000626	0.00596	CcSEcCtD
Bosutinib—Respiratory failure—Temozolomide—brain cancer	0.000625	0.00596	CcSEcCtD
Bosutinib—Renal failure acute—Hydroxyurea—brain cancer	0.000618	0.00589	CcSEcCtD
Bosutinib—Pancytopenia—Procarbazine—brain cancer	0.000605	0.00576	CcSEcCtD
Bosutinib—ERBB3—Podofilox—Etoposide—brain cancer	0.000572	0.158	CbGdCrCtD
Bosutinib—Pneumonia—Procarbazine—brain cancer	0.000571	0.00544	CcSEcCtD
Bosutinib—Infection—Lomustine—brain cancer	0.000567	0.0054	CcSEcCtD
Bosutinib—Thrombocytopenia—Lomustine—brain cancer	0.000558	0.00532	CcSEcCtD
Bosutinib—Pain—Carboplatin—brain cancer	0.000558	0.00531	CcSEcCtD
Bosutinib—Chest discomfort—Etoposide—brain cancer	0.000555	0.00529	CcSEcCtD
Bosutinib—Face oedema—Hydroxyurea—brain cancer	0.000551	0.00525	CcSEcCtD
Bosutinib—Blood creatinine increased—Hydroxyurea—brain cancer	0.000534	0.00509	CcSEcCtD
Bosutinib—Body temperature increased—Carboplatin—brain cancer	0.000515	0.00491	CcSEcCtD
Bosutinib—Decreased appetite—Lomustine—brain cancer	0.000496	0.00473	CcSEcCtD
Bosutinib—Pancytopenia—Hydroxyurea—brain cancer	0.000468	0.00446	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Carmustine—brain cancer	0.000461	0.00439	CcSEcCtD
Bosutinib—Neutropenia—Hydroxyurea—brain cancer	0.000461	0.00439	CcSEcCtD
Bosutinib—Body temperature increased—Lomustine—brain cancer	0.000451	0.0043	CcSEcCtD
Bosutinib—Rash maculo-papular—Etoposide—brain cancer	0.000446	0.00425	CcSEcCtD
Bosutinib—Face oedema—Carmustine—brain cancer	0.000445	0.00424	CcSEcCtD
Bosutinib—Infestation—Hydroxyurea—brain cancer	0.000439	0.00419	CcSEcCtD
Bosutinib—Infestation NOS—Hydroxyurea—brain cancer	0.000439	0.00419	CcSEcCtD
Bosutinib—Face oedema—Temozolomide—brain cancer	0.00043	0.0041	CcSEcCtD
Bosutinib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.000416	0.00396	CcSEcCtD
Bosutinib—Dehydration—Temozolomide—brain cancer	0.000414	0.00395	CcSEcCtD
Bosutinib—Anaemia—Procarbazine—brain cancer	0.00041	0.00391	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000401	0.00382	CcSEcCtD
Bosutinib—Leukopenia—Procarbazine—brain cancer	0.000397	0.00379	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000393	0.00374	CcSEcCtD
Bosutinib—Cough—Procarbazine—brain cancer	0.000387	0.00369	CcSEcCtD
Bosutinib—CHEK2—Podofilox—Etoposide—brain cancer	0.000386	0.107	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—brain cancer	0.000386	0.107	CbGdCrCtD
Bosutinib—Pancytopenia—Carmustine—brain cancer	0.000378	0.00361	CcSEcCtD
Bosutinib—Myalgia—Procarbazine—brain cancer	0.000378	0.0036	CcSEcCtD
Bosutinib—Arthralgia—Procarbazine—brain cancer	0.000378	0.0036	CcSEcCtD
Bosutinib—Neutropenia—Carmustine—brain cancer	0.000373	0.00355	CcSEcCtD
Bosutinib—Bronchitis—Temozolomide—brain cancer	0.00037	0.00353	CcSEcCtD
Bosutinib—Pancytopenia—Temozolomide—brain cancer	0.000366	0.00348	CcSEcCtD
Bosutinib—Vomiting—Lomustine—brain cancer	0.000363	0.00346	CcSEcCtD
Bosutinib—Oedema—Procarbazine—brain cancer	0.000362	0.00345	CcSEcCtD
Bosutinib—Neutropenia—Temozolomide—brain cancer	0.00036	0.00343	CcSEcCtD
Bosutinib—Infection—Procarbazine—brain cancer	0.00036	0.00343	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Temozolomide—brain cancer	0.000358	0.00341	CcSEcCtD
Bosutinib—Pneumonia—Carmustine—brain cancer	0.000357	0.00341	CcSEcCtD
Bosutinib—Thrombocytopenia—Procarbazine—brain cancer	0.000355	0.00338	CcSEcCtD
Bosutinib—Renal failure—Carmustine—brain cancer	0.000349	0.00333	CcSEcCtD
Bosutinib—Pneumonia—Temozolomide—brain cancer	0.000345	0.00329	CcSEcCtD
Bosutinib—Infestation NOS—Temozolomide—brain cancer	0.000343	0.00327	CcSEcCtD
Bosutinib—Infestation—Temozolomide—brain cancer	0.000343	0.00327	CcSEcCtD
Bosutinib—Nausea—Lomustine—brain cancer	0.000339	0.00323	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00033	0.00314	CcSEcCtD
Bosutinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000325	0.00309	CcSEcCtD
Bosutinib—Ill-defined disorder—Hydroxyurea—brain cancer	0.000319	0.00304	CcSEcCtD
Bosutinib—Anaemia—Hydroxyurea—brain cancer	0.000317	0.00303	CcSEcCtD
Bosutinib—Decreased appetite—Procarbazine—brain cancer	0.000315	0.003	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000314	0.003	CcSEcCtD
Bosutinib—Oedema peripheral—Carmustine—brain cancer	0.000314	0.00299	CcSEcCtD
Bosutinib—Connective tissue disorder—Carmustine—brain cancer	0.000313	0.00299	CcSEcCtD
Bosutinib—Fatigue—Procarbazine—brain cancer	0.000312	0.00298	CcSEcCtD
Bosutinib—Malaise—Hydroxyurea—brain cancer	0.00031	0.00295	CcSEcCtD
Bosutinib—Pain—Procarbazine—brain cancer	0.00031	0.00295	CcSEcCtD
Bosutinib—Hepatitis—Temozolomide—brain cancer	0.000308	0.00294	CcSEcCtD
Bosutinib—Leukopenia—Hydroxyurea—brain cancer	0.000307	0.00293	CcSEcCtD
Bosutinib—Urinary tract disorder—Temozolomide—brain cancer	0.000304	0.0029	CcSEcCtD
Bosutinib—Oedema peripheral—Temozolomide—brain cancer	0.000304	0.00289	CcSEcCtD
Bosutinib—Connective tissue disorder—Temozolomide—brain cancer	0.000303	0.00289	CcSEcCtD
Bosutinib—Urethral disorder—Temozolomide—brain cancer	0.000302	0.00288	CcSEcCtD
Bosutinib—Feeling abnormal—Procarbazine—brain cancer	0.000298	0.00284	CcSEcCtD
Bosutinib—Gastrointestinal pain—Procarbazine—brain cancer	0.000296	0.00282	CcSEcCtD
Bosutinib—Pancytopenia—Etoposide—brain cancer	0.000293	0.00279	CcSEcCtD
Bosutinib—Erythema multiforme—Temozolomide—brain cancer	0.000291	0.00278	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00029	0.00277	CcSEcCtD
Bosutinib—Discomfort—Hydroxyurea—brain cancer	0.000289	0.00275	CcSEcCtD
Bosutinib—Neutropenia—Etoposide—brain cancer	0.000288	0.00275	CcSEcCtD
Bosutinib—Urticaria—Procarbazine—brain cancer	0.000288	0.00274	CcSEcCtD
Bosutinib—Tinnitus—Temozolomide—brain cancer	0.000287	0.00274	CcSEcCtD
Bosutinib—Abdominal pain—Procarbazine—brain cancer	0.000286	0.00273	CcSEcCtD
Bosutinib—Body temperature increased—Procarbazine—brain cancer	0.000286	0.00273	CcSEcCtD
Bosutinib—Cardiac disorder—Temozolomide—brain cancer	0.000286	0.00273	CcSEcCtD
Bosutinib—Oedema—Hydroxyurea—brain cancer	0.00028	0.00267	CcSEcCtD
Bosutinib—Infection—Hydroxyurea—brain cancer	0.000278	0.00265	CcSEcCtD
Bosutinib—Immune system disorder—Temozolomide—brain cancer	0.000278	0.00265	CcSEcCtD
Bosutinib—Mediastinal disorder—Temozolomide—brain cancer	0.000278	0.00265	CcSEcCtD
Bosutinib—Malnutrition—Carmustine—brain cancer	0.000278	0.00265	CcSEcCtD
Bosutinib—Pneumonia—Etoposide—brain cancer	0.000276	0.00263	CcSEcCtD
Bosutinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000275	0.00262	CcSEcCtD
Bosutinib—Infestation NOS—Etoposide—brain cancer	0.000275	0.00262	CcSEcCtD
Bosutinib—Infestation—Etoposide—brain cancer	0.000275	0.00262	CcSEcCtD
Bosutinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000274	0.00262	CcSEcCtD
Bosutinib—Skin disorder—Hydroxyurea—brain cancer	0.000272	0.00259	CcSEcCtD
Bosutinib—Renal failure—Etoposide—brain cancer	0.00027	0.00257	CcSEcCtD
Bosutinib—Back pain—Carmustine—brain cancer	0.000269	0.00256	CcSEcCtD
Bosutinib—Malnutrition—Temozolomide—brain cancer	0.000268	0.00256	CcSEcCtD
Bosutinib—Dysgeusia—Temozolomide—brain cancer	0.000263	0.0025	CcSEcCtD
Bosutinib—Asthenia—Procarbazine—brain cancer	0.00026	0.00248	CcSEcCtD
Bosutinib—Hepatobiliary disease—Etoposide—brain cancer	0.00026	0.00248	CcSEcCtD
Bosutinib—Back pain—Temozolomide—brain cancer	0.00026	0.00247	CcSEcCtD
Bosutinib—Anaemia—Carmustine—brain cancer	0.000257	0.00245	CcSEcCtD
Bosutinib—Agranulocytosis—Etoposide—brain cancer	0.000256	0.00244	CcSEcCtD
Bosutinib—Pruritus—Procarbazine—brain cancer	0.000256	0.00244	CcSEcCtD
Bosutinib—Dyspnoea—Hydroxyurea—brain cancer	0.00025	0.00238	CcSEcCtD
Bosutinib—Ill-defined disorder—Temozolomide—brain cancer	0.000249	0.00237	CcSEcCtD
Bosutinib—Leukopenia—Carmustine—brain cancer	0.000248	0.00237	CcSEcCtD
Bosutinib—Anaemia—Temozolomide—brain cancer	0.000248	0.00236	CcSEcCtD
Bosutinib—Diarrhoea—Procarbazine—brain cancer	0.000248	0.00236	CcSEcCtD
Bosutinib—Decreased appetite—Hydroxyurea—brain cancer	0.000244	0.00232	CcSEcCtD
Bosutinib—Urinary tract disorder—Etoposide—brain cancer	0.000244	0.00232	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000242	0.00231	CcSEcCtD
Bosutinib—Malaise—Temozolomide—brain cancer	0.000242	0.00231	CcSEcCtD
Bosutinib—Urethral disorder—Etoposide—brain cancer	0.000242	0.0023	CcSEcCtD
Bosutinib—Fatigue—Hydroxyurea—brain cancer	0.000242	0.0023	CcSEcCtD
Bosutinib—Leukopenia—Temozolomide—brain cancer	0.00024	0.00229	CcSEcCtD
Bosutinib—Pain—Hydroxyurea—brain cancer	0.00024	0.00228	CcSEcCtD
Bosutinib—Dizziness—Procarbazine—brain cancer	0.000239	0.00228	CcSEcCtD
Bosutinib—Chest pain—Carmustine—brain cancer	0.000236	0.00225	CcSEcCtD
Bosutinib—Myalgia—Carmustine—brain cancer	0.000236	0.00225	CcSEcCtD
Bosutinib—Cough—Temozolomide—brain cancer	0.000234	0.00223	CcSEcCtD
Bosutinib—Erythema multiforme—Etoposide—brain cancer	0.000233	0.00222	CcSEcCtD
Bosutinib—Feeling abnormal—Hydroxyurea—brain cancer	0.000231	0.0022	CcSEcCtD
Bosutinib—Vomiting—Procarbazine—brain cancer	0.00023	0.00219	CcSEcCtD
Bosutinib—Cardiac disorder—Etoposide—brain cancer	0.000229	0.00218	CcSEcCtD
Bosutinib—Arthralgia—Temozolomide—brain cancer	0.000228	0.00218	CcSEcCtD
Bosutinib—Myalgia—Temozolomide—brain cancer	0.000228	0.00218	CcSEcCtD
Bosutinib—Rash—Procarbazine—brain cancer	0.000228	0.00218	CcSEcCtD
Bosutinib—Dermatitis—Procarbazine—brain cancer	0.000228	0.00217	CcSEcCtD
Bosutinib—Headache—Procarbazine—brain cancer	0.000227	0.00216	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000227	0.00216	CcSEcCtD
Bosutinib—Oedema—Carmustine—brain cancer	0.000227	0.00216	CcSEcCtD
Bosutinib—Discomfort—Temozolomide—brain cancer	0.000226	0.00215	CcSEcCtD
Bosutinib—Infection—Carmustine—brain cancer	0.000225	0.00215	CcSEcCtD
Bosutinib—Immune system disorder—Etoposide—brain cancer	0.000223	0.00212	CcSEcCtD
Bosutinib—Mediastinal disorder—Etoposide—brain cancer	0.000222	0.00212	CcSEcCtD
Bosutinib—Thrombocytopenia—Carmustine—brain cancer	0.000222	0.00211	CcSEcCtD
Bosutinib—Body temperature increased—Hydroxyurea—brain cancer	0.000222	0.00211	CcSEcCtD
Bosutinib—Oedema—Temozolomide—brain cancer	0.000219	0.00209	CcSEcCtD
Bosutinib—Anaphylactic shock—Temozolomide—brain cancer	0.000219	0.00209	CcSEcCtD
Bosutinib—Infection—Temozolomide—brain cancer	0.000218	0.00207	CcSEcCtD
Bosutinib—Nausea—Procarbazine—brain cancer	0.000215	0.00205	CcSEcCtD
Bosutinib—Nervous system disorder—Temozolomide—brain cancer	0.000215	0.00205	CcSEcCtD
Bosutinib—Thrombocytopenia—Temozolomide—brain cancer	0.000214	0.00204	CcSEcCtD
Bosutinib—Skin disorder—Temozolomide—brain cancer	0.000213	0.00203	CcSEcCtD
Bosutinib—Dysgeusia—Etoposide—brain cancer	0.00021	0.002	CcSEcCtD
Bosutinib—Back pain—Etoposide—brain cancer	0.000208	0.00198	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000206	0.00197	CcSEcCtD
Bosutinib—Dyspnoea—Carmustine—brain cancer	0.000202	0.00193	CcSEcCtD
Bosutinib—Asthenia—Hydroxyurea—brain cancer	0.000201	0.00192	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000199	0.0019	CcSEcCtD
Bosutinib—Ill-defined disorder—Etoposide—brain cancer	0.000199	0.0019	CcSEcCtD
Bosutinib—Anaemia—Etoposide—brain cancer	0.000198	0.00189	CcSEcCtD
Bosutinib—Decreased appetite—Carmustine—brain cancer	0.000197	0.00188	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000196	0.00186	CcSEcCtD
Bosutinib—Dyspnoea—Temozolomide—brain cancer	0.000195	0.00186	CcSEcCtD
Bosutinib—Pain—Carmustine—brain cancer	0.000194	0.00185	CcSEcCtD
Bosutinib—Malaise—Etoposide—brain cancer	0.000194	0.00185	CcSEcCtD
Bosutinib—Leukopenia—Etoposide—brain cancer	0.000192	0.00183	CcSEcCtD
Bosutinib—Diarrhoea—Hydroxyurea—brain cancer	0.000192	0.00183	CcSEcCtD
Bosutinib—Decreased appetite—Temozolomide—brain cancer	0.00019	0.00181	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000189	0.0018	CcSEcCtD
Bosutinib—Fatigue—Temozolomide—brain cancer	0.000189	0.0018	CcSEcCtD
Bosutinib—Cough—Etoposide—brain cancer	0.000187	0.00179	CcSEcCtD
Bosutinib—Pain—Temozolomide—brain cancer	0.000187	0.00178	CcSEcCtD
Bosutinib—Feeling abnormal—Carmustine—brain cancer	0.000187	0.00178	CcSEcCtD
Bosutinib—Dizziness—Hydroxyurea—brain cancer	0.000185	0.00177	CcSEcCtD
Bosutinib—Gastrointestinal pain—Carmustine—brain cancer	0.000185	0.00177	CcSEcCtD
Bosutinib—Chest pain—Etoposide—brain cancer	0.000183	0.00174	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000182	0.00173	CcSEcCtD
Bosutinib—Discomfort—Etoposide—brain cancer	0.000181	0.00172	CcSEcCtD
Bosutinib—Feeling abnormal—Temozolomide—brain cancer	0.00018	0.00172	CcSEcCtD
Bosutinib—Abdominal pain—Carmustine—brain cancer	0.000179	0.00171	CcSEcCtD
Bosutinib—Body temperature increased—Carmustine—brain cancer	0.000179	0.00171	CcSEcCtD
Bosutinib—Gastrointestinal pain—Temozolomide—brain cancer	0.000179	0.00171	CcSEcCtD
Bosutinib—Vomiting—Hydroxyurea—brain cancer	0.000178	0.0017	CcSEcCtD
Bosutinib—Rash—Hydroxyurea—brain cancer	0.000177	0.00168	CcSEcCtD
Bosutinib—Dermatitis—Hydroxyurea—brain cancer	0.000177	0.00168	CcSEcCtD
Bosutinib—Headache—Hydroxyurea—brain cancer	0.000176	0.00167	CcSEcCtD
Bosutinib—Anaphylactic shock—Etoposide—brain cancer	0.000175	0.00167	CcSEcCtD
Bosutinib—Infection—Etoposide—brain cancer	0.000174	0.00166	CcSEcCtD
Bosutinib—Urticaria—Temozolomide—brain cancer	0.000174	0.00166	CcSEcCtD
Bosutinib—Abdominal pain—Temozolomide—brain cancer	0.000173	0.00165	CcSEcCtD
Bosutinib—Body temperature increased—Temozolomide—brain cancer	0.000173	0.00165	CcSEcCtD
Bosutinib—Thrombocytopenia—Etoposide—brain cancer	0.000172	0.00163	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—brain cancer	0.00017	0.00162	CcSEcCtD
Bosutinib—Nausea—Hydroxyurea—brain cancer	0.000166	0.00159	CcSEcCtD
Bosutinib—Asthenia—Carmustine—brain cancer	0.000163	0.00155	CcSEcCtD
Bosutinib—Asthenia—Temozolomide—brain cancer	0.000157	0.0015	CcSEcCtD
Bosutinib—Dyspnoea—Etoposide—brain cancer	0.000156	0.00149	CcSEcCtD
Bosutinib—Diarrhoea—Carmustine—brain cancer	0.000155	0.00148	CcSEcCtD
Bosutinib—Pruritus—Temozolomide—brain cancer	0.000155	0.00148	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—brain cancer	0.000152	0.00145	CcSEcCtD
Bosutinib—MAP4K4—cerebellum—brain cancer	0.000152	0.000996	CbGeAlD
Bosutinib—YES1—gonad—brain cancer	0.000152	0.000995	CbGeAlD
Bosutinib—Gastrointestinal disorder—Etoposide—brain cancer	0.000151	0.00144	CcSEcCtD
Bosutinib—STK4—brain—brain cancer	0.000151	0.000993	CbGeAlD
Bosutinib—Fatigue—Etoposide—brain cancer	0.000151	0.00144	CcSEcCtD
Bosutinib—AXL—spinal cord—brain cancer	0.000151	0.000989	CbGeAlD
Bosutinib—BCR—cerebellum—brain cancer	0.000151	0.000989	CbGeAlD
Bosutinib—NUAK2—cerebellum—brain cancer	0.000151	0.000989	CbGeAlD
Bosutinib—CSNK1E—head—brain cancer	0.00015	0.000987	CbGeAlD
Bosutinib—STK10—gonad—brain cancer	0.00015	0.000986	CbGeAlD
Bosutinib—MAP2K1—central nervous system—brain cancer	0.00015	0.000985	CbGeAlD
Bosutinib—STK35—central nervous system—brain cancer	0.00015	0.000985	CbGeAlD
Bosutinib—SIK1—endocrine gland—brain cancer	0.00015	0.000984	CbGeAlD
Bosutinib—Dizziness—Carmustine—brain cancer	0.00015	0.00143	CcSEcCtD
Bosutinib—Pain—Etoposide—brain cancer	0.00015	0.00143	CcSEcCtD
Bosutinib—Diarrhoea—Temozolomide—brain cancer	0.00015	0.00143	CcSEcCtD
Bosutinib—MAP3K12—cerebellum—brain cancer	0.00015	0.000982	CbGeAlD
Bosutinib—CAMK1D—brain—brain cancer	0.000149	0.000981	CbGeAlD
Bosutinib—CSK—central nervous system—brain cancer	0.000149	0.000978	CbGeAlD
Bosutinib—SLK—midbrain—brain cancer	0.000149	0.000976	CbGeAlD
Bosutinib—EPHA4—endocrine gland—brain cancer	0.000148	0.000974	CbGeAlD
Bosutinib—CSNK1A1—central nervous system—brain cancer	0.000148	0.000972	CbGeAlD
Bosutinib—SIK1—head—brain cancer	0.000148	0.000971	CbGeAlD
Bosutinib—IRAK4—head—brain cancer	0.000148	0.000971	CbGeAlD
Bosutinib—YES1—pituitary gland—brain cancer	0.000148	0.000971	CbGeAlD
Bosutinib—STK24—brain—brain cancer	0.000148	0.00097	CbGeAlD
Bosutinib—EPHB4—midbrain—brain cancer	0.000148	0.000969	CbGeAlD
Bosutinib—HCK—central nervous system—brain cancer	0.000147	0.000966	CbGeAlD
Bosutinib—CLK1—central nervous system—brain cancer	0.000147	0.000966	CbGeAlD
Bosutinib—ERBB3—endocrine gland—brain cancer	0.000147	0.000964	CbGeAlD
Bosutinib—STK35—cerebellum—brain cancer	0.000147	0.000962	CbGeAlD
Bosutinib—MAP2K1—cerebellum—brain cancer	0.000147	0.000962	CbGeAlD
Bosutinib—MAP2K2—endocrine gland—brain cancer	0.000147	0.000962	CbGeAlD
Bosutinib—ULK3—endocrine gland—brain cancer	0.000147	0.000962	CbGeAlD
Bosutinib—EPHA4—head—brain cancer	0.000146	0.000961	CbGeAlD
Bosutinib—TAOK3—pituitary gland—brain cancer	0.000146	0.000959	CbGeAlD
Bosutinib—SRC—gonad—brain cancer	0.000146	0.000958	CbGeAlD
Bosutinib—CSK—cerebellum—brain cancer	0.000146	0.000956	CbGeAlD
Bosutinib—MAP3K2—endocrine gland—brain cancer	0.000145	0.000955	CbGeAlD
Bosutinib—SLK—spinal cord—brain cancer	0.000145	0.000952	CbGeAlD
Bosutinib—ERBB3—head—brain cancer	0.000145	0.000952	CbGeAlD
Bosutinib—Dizziness—Temozolomide—brain cancer	0.000145	0.00138	CcSEcCtD
Bosutinib—CSNK1A1—cerebellum—brain cancer	0.000145	0.00095	CbGeAlD
Bosutinib—ULK3—head—brain cancer	0.000145	0.00095	CbGeAlD
Bosutinib—MAP2K2—head—brain cancer	0.000145	0.00095	CbGeAlD
Bosutinib—FYN—midbrain—brain cancer	0.000145	0.000949	CbGeAlD
Bosutinib—BMP2K—central nervous system—brain cancer	0.000144	0.000948	CbGeAlD
Bosutinib—CAMK2G—central nervous system—brain cancer	0.000144	0.000948	CbGeAlD
Bosutinib—Feeling abnormal—Etoposide—brain cancer	0.000144	0.00138	CcSEcCtD
Bosutinib—Vomiting—Carmustine—brain cancer	0.000144	0.00137	CcSEcCtD
Bosutinib—EPHB4—spinal cord—brain cancer	0.000144	0.000946	CbGeAlD
Bosutinib—CLK1—cerebellum—brain cancer	0.000144	0.000944	CbGeAlD
Bosutinib—MAP3K2—head—brain cancer	0.000144	0.000943	CbGeAlD
Bosutinib—Gastrointestinal pain—Etoposide—brain cancer	0.000143	0.00137	CcSEcCtD
Bosutinib—LRRK2—central nervous system—brain cancer	0.000143	0.000939	CbGeAlD
Bosutinib—ALK—brain—brain cancer	0.000143	0.000938	CbGeAlD
Bosutinib—TYRO3—brain—brain cancer	0.000143	0.000938	CbGeAlD
Bosutinib—EPHA5—brain—brain cancer	0.000143	0.000938	CbGeAlD
Bosutinib—FER—brain—brain cancer	0.000143	0.000938	CbGeAlD
Bosutinib—ABL2—cerebellum—brain cancer	0.000143	0.000938	CbGeAlD
Bosutinib—Rash—Carmustine—brain cancer	0.000143	0.00136	CcSEcCtD
Bosutinib—YES1—medulla oblongata—brain cancer	0.000143	0.000937	CbGeAlD
Bosutinib—Dermatitis—Carmustine—brain cancer	0.000143	0.00136	CcSEcCtD
Bosutinib—TBK1—endocrine gland—brain cancer	0.000142	0.000935	CbGeAlD
Bosutinib—PTK2—endocrine gland—brain cancer	0.000142	0.000935	CbGeAlD
Bosutinib—LYN—brain—brain cancer	0.000142	0.000933	CbGeAlD
Bosutinib—Headache—Carmustine—brain cancer	0.000142	0.00135	CcSEcCtD
Bosutinib—MAP4K5—midbrain—brain cancer	0.000141	0.000927	CbGeAlD
Bosutinib—MAP3K3—midbrain—brain cancer	0.000141	0.000927	CbGeAlD
Bosutinib—BMP2K—cerebellum—brain cancer	0.000141	0.000926	CbGeAlD
Bosutinib—CAMK2G—cerebellum—brain cancer	0.000141	0.000926	CbGeAlD
Bosutinib—FYN—spinal cord—brain cancer	0.000141	0.000926	CbGeAlD
Bosutinib—TAOK3—medulla oblongata—brain cancer	0.000141	0.000925	CbGeAlD
Bosutinib—PTK2—head—brain cancer	0.000141	0.000923	CbGeAlD
Bosutinib—TBK1—head—brain cancer	0.000141	0.000923	CbGeAlD
Bosutinib—MAP4K1—brain—brain cancer	0.00014	0.000919	CbGeAlD
Bosutinib—MAP3K19—brain—brain cancer	0.00014	0.000919	CbGeAlD
Bosutinib—LRRK2—cerebellum—brain cancer	0.00014	0.000918	CbGeAlD
Bosutinib—ABL1—brainstem—brain cancer	0.00014	0.000918	CbGeAlD
Bosutinib—EGFR—cerebellum—brain cancer	0.000139	0.000915	CbGeAlD
Bosutinib—PTK2B—central nervous system—brain cancer	0.000139	0.000915	CbGeAlD
Bosutinib—BTK—brain—brain cancer	0.000139	0.000915	CbGeAlD
Bosutinib—Vomiting—Temozolomide—brain cancer	0.000139	0.00133	CcSEcCtD
Bosutinib—PDGFRB—telencephalon—brain cancer	0.000139	0.000914	CbGeAlD
Bosutinib—Urticaria—Etoposide—brain cancer	0.000139	0.00133	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—brain cancer	0.000139	0.00132	CcSEcCtD
Bosutinib—Abdominal pain—Etoposide—brain cancer	0.000139	0.00132	CcSEcCtD
Bosutinib—Rash—Temozolomide—brain cancer	0.000138	0.00132	CcSEcCtD
Bosutinib—Dermatitis—Temozolomide—brain cancer	0.000138	0.00131	CcSEcCtD
Bosutinib—MAP3K3—spinal cord—brain cancer	0.000138	0.000905	CbGeAlD
Bosutinib—MAP4K5—spinal cord—brain cancer	0.000138	0.000905	CbGeAlD
Bosutinib—TNK2—brain—brain cancer	0.000137	0.000902	CbGeAlD
Bosutinib—CSNK1E—central nervous system—brain cancer	0.000137	0.0009	CbGeAlD
Bosutinib—Headache—Temozolomide—brain cancer	0.000137	0.00131	CcSEcCtD
Bosutinib—RPS6KB1—endocrine gland—brain cancer	0.000137	0.0009	CbGeAlD
Bosutinib—PTK2B—cerebellum—brain cancer	0.000136	0.000895	CbGeAlD
Bosutinib—FGR—endocrine gland—brain cancer	0.000136	0.000894	CbGeAlD
Bosutinib—AXL—endocrine gland—brain cancer	0.000136	0.000891	CbGeAlD
Bosutinib—MAP4K2—brain—brain cancer	0.000135	0.000889	CbGeAlD
Bosutinib—RPS6KB1—head—brain cancer	0.000135	0.000888	CbGeAlD
Bosutinib—IRAK4—central nervous system—brain cancer	0.000135	0.000886	CbGeAlD
Bosutinib—SIK1—central nervous system—brain cancer	0.000135	0.000886	CbGeAlD
Bosutinib—Nausea—Carmustine—brain cancer	0.000135	0.00128	CcSEcCtD
Bosutinib—FGR—head—brain cancer	0.000135	0.000883	CbGeAlD
Bosutinib—CSNK1E—cerebellum—brain cancer	0.000134	0.00088	CbGeAlD
Bosutinib—AXL—head—brain cancer	0.000134	0.000879	CbGeAlD
Bosutinib—EPHA4—central nervous system—brain cancer	0.000134	0.000878	CbGeAlD
Bosutinib—ERBB4—brain—brain cancer	0.000134	0.000877	CbGeAlD
Bosutinib—STK3—brain—brain cancer	0.000134	0.000877	CbGeAlD
Bosutinib—ERBB3—central nervous system—brain cancer	0.000132	0.000869	CbGeAlD
Bosutinib—ULK3—central nervous system—brain cancer	0.000132	0.000867	CbGeAlD
Bosutinib—MAP2K2—central nervous system—brain cancer	0.000132	0.000867	CbGeAlD
Bosutinib—SIK1—cerebellum—brain cancer	0.000132	0.000866	CbGeAlD
Bosutinib—IRAK4—cerebellum—brain cancer	0.000132	0.000866	CbGeAlD
Bosutinib—ROCK1—brain—brain cancer	0.000132	0.000866	CbGeAlD
Bosutinib—MAP3K2—central nervous system—brain cancer	0.000131	0.000861	CbGeAlD
Bosutinib—CSF1R—gonad—brain cancer	0.000131	0.00086	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—brain cancer	0.000131	0.000859	CbGeAlD
Bosutinib—EPHA4—cerebellum—brain cancer	0.000131	0.000858	CbGeAlD
Bosutinib—YES1—midbrain—brain cancer	0.00013	0.000857	CbGeAlD
Bosutinib—Nausea—Temozolomide—brain cancer	0.00013	0.00124	CcSEcCtD
Bosutinib—EPHB4—endocrine gland—brain cancer	0.00013	0.000851	CbGeAlD
Bosutinib—ERBB3—cerebellum—brain cancer	0.000129	0.000849	CbGeAlD
Bosutinib—MAP2K2—cerebellum—brain cancer	0.000129	0.000847	CbGeAlD
Bosutinib—ULK3—cerebellum—brain cancer	0.000129	0.000847	CbGeAlD
Bosutinib—TAOK3—midbrain—brain cancer	0.000129	0.000846	CbGeAlD
Bosutinib—PTK2—central nervous system—brain cancer	0.000128	0.000843	CbGeAlD
Bosutinib—TBK1—central nervous system—brain cancer	0.000128	0.000843	CbGeAlD
Bosutinib—MAP3K2—cerebellum—brain cancer	0.000128	0.000841	CbGeAlD
Bosutinib—BMPR2—brain—brain cancer	0.000128	0.000841	CbGeAlD
Bosutinib—CSF1R—pituitary gland—brain cancer	0.000128	0.000839	CbGeAlD
Bosutinib—YES1—spinal cord—brain cancer	0.000127	0.000836	CbGeAlD
Bosutinib—EPHA2—endocrine gland—brain cancer	0.000127	0.000835	CbGeAlD
Bosutinib—STK36—brain—brain cancer	0.000127	0.000834	CbGeAlD
Bosutinib—EPHB3—brain—brain cancer	0.000127	0.000834	CbGeAlD
Bosutinib—FYN—endocrine gland—brain cancer	0.000127	0.000834	CbGeAlD
Bosutinib—MAP3K7—cerebellum—brain cancer	0.000127	0.000833	CbGeAlD
Bosutinib—MAP2K5—medulla oblongata—brain cancer	0.000126	0.000829	CbGeAlD
Bosutinib—Asthenia—Etoposide—brain cancer	0.000126	0.0012	CcSEcCtD
Bosutinib—TAOK3—spinal cord—brain cancer	0.000126	0.000825	CbGeAlD
Bosutinib—MERTK—brain—brain cancer	0.000126	0.000825	CbGeAlD
Bosutinib—EPHA2—head—brain cancer	0.000126	0.000824	CbGeAlD
Bosutinib—PTK2—cerebellum—brain cancer	0.000126	0.000824	CbGeAlD
Bosutinib—TBK1—cerebellum—brain cancer	0.000126	0.000824	CbGeAlD
Bosutinib—FYN—head—brain cancer	0.000125	0.000823	CbGeAlD
Bosutinib—MAP3K3—endocrine gland—brain cancer	0.000124	0.000815	CbGeAlD
Bosutinib—MAP4K5—endocrine gland—brain cancer	0.000124	0.000815	CbGeAlD
Bosutinib—ABL1—telencephalon—brain cancer	0.000124	0.000814	CbGeAlD
Bosutinib—Pruritus—Etoposide—brain cancer	0.000124	0.00118	CcSEcCtD
Bosutinib—RPS6KB1—central nervous system—brain cancer	0.000124	0.000811	CbGeAlD
Bosutinib—CSF1R—medulla oblongata—brain cancer	0.000123	0.000809	CbGeAlD
Bosutinib—MAP4K4—brain—brain cancer	0.000123	0.000809	CbGeAlD
Bosutinib—IRAK1—cerebellum—brain cancer	0.000123	0.000808	CbGeAlD
Bosutinib—FGR—central nervous system—brain cancer	0.000123	0.000806	CbGeAlD
Bosutinib—MAP4K5—head—brain cancer	0.000123	0.000804	CbGeAlD
Bosutinib—MAP3K3—head—brain cancer	0.000123	0.000804	CbGeAlD
Bosutinib—SRC—spinal cord—brain cancer	0.000122	0.000804	CbGeAlD
Bosutinib—NUAK2—brain—brain cancer	0.000122	0.000804	CbGeAlD
Bosutinib—BCR—brain—brain cancer	0.000122	0.000804	CbGeAlD
Bosutinib—AXL—central nervous system—brain cancer	0.000122	0.000803	CbGeAlD
Bosutinib—MAP3K12—brain—brain cancer	0.000122	0.000798	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—brain cancer	0.000121	0.000792	CbGeAlD
Bosutinib—Diarrhoea—Etoposide—brain cancer	0.00012	0.00114	CcSEcCtD
Bosutinib—AXL—cerebellum—brain cancer	0.00012	0.000784	CbGeAlD
Bosutinib—MAP2K1—brain—brain cancer	0.000119	0.000782	CbGeAlD
Bosutinib—STK35—brain—brain cancer	0.000119	0.000782	CbGeAlD
Bosutinib—CSK—brain—brain cancer	0.000118	0.000777	CbGeAlD
Bosutinib—CSNK1A1—brain—brain cancer	0.000118	0.000771	CbGeAlD
Bosutinib—CLK1—brain—brain cancer	0.000117	0.000767	CbGeAlD
Bosutinib—HCK—brain—brain cancer	0.000117	0.000767	CbGeAlD
Bosutinib—PDGFRB—gonad—brain cancer	0.000116	0.000762	CbGeAlD
Bosutinib—ABL2—brain—brain cancer	0.000116	0.000762	CbGeAlD
Bosutinib—Dizziness—Etoposide—brain cancer	0.000116	0.0011	CcSEcCtD
Bosutinib—MAP2K5—midbrain—brain cancer	0.000115	0.000758	CbGeAlD
Bosutinib—SLK—cerebellum—brain cancer	0.000115	0.000755	CbGeAlD
Bosutinib—EPHA2—central nervous system—brain cancer	0.000115	0.000752	CbGeAlD
Bosutinib—CAMK2G—brain—brain cancer	0.000115	0.000752	CbGeAlD
Bosutinib—BMP2K—brain—brain cancer	0.000115	0.000752	CbGeAlD
Bosutinib—YES1—endocrine gland—brain cancer	0.000115	0.000752	CbGeAlD
Bosutinib—FYN—central nervous system—brain cancer	0.000114	0.000751	CbGeAlD
Bosutinib—EPHB4—cerebellum—brain cancer	0.000114	0.00075	CbGeAlD
Bosutinib—LRRK2—brain—brain cancer	0.000114	0.000746	CbGeAlD
Bosutinib—STK10—endocrine gland—brain cancer	0.000114	0.000746	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—brain cancer	0.000113	0.000744	CbGeAlD
Bosutinib—EGFR—brain—brain cancer	0.000113	0.000743	CbGeAlD
Bosutinib—YES1—head—brain cancer	0.000113	0.000743	CbGeAlD
Bosutinib—TAOK3—endocrine gland—brain cancer	0.000113	0.000743	CbGeAlD
Bosutinib—CSF1R—midbrain—brain cancer	0.000113	0.00074	CbGeAlD
Bosutinib—MAP2K5—spinal cord—brain cancer	0.000113	0.00074	CbGeAlD
Bosutinib—STK10—head—brain cancer	0.000112	0.000736	CbGeAlD
Bosutinib—FYN—cerebellum—brain cancer	0.000112	0.000734	CbGeAlD
Bosutinib—MAP3K3—central nervous system—brain cancer	0.000112	0.000734	CbGeAlD
Bosutinib—MAP4K5—central nervous system—brain cancer	0.000112	0.000734	CbGeAlD
Bosutinib—TAOK3—head—brain cancer	0.000112	0.000733	CbGeAlD
Bosutinib—Vomiting—Etoposide—brain cancer	0.000111	0.00106	CcSEcCtD
Bosutinib—PTK2B—brain—brain cancer	0.000111	0.000727	CbGeAlD
Bosutinib—Rash—Etoposide—brain cancer	0.00011	0.00105	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—brain cancer	0.00011	0.00105	CcSEcCtD
Bosutinib—SRC—endocrine gland—brain cancer	0.00011	0.000724	CbGeAlD
Bosutinib—CSF1R—spinal cord—brain cancer	0.00011	0.000722	CbGeAlD
Bosutinib—Headache—Etoposide—brain cancer	0.00011	0.00105	CcSEcCtD
Bosutinib—PDGFRB—medulla oblongata—brain cancer	0.000109	0.000718	CbGeAlD
Bosutinib—MAP3K3—cerebellum—brain cancer	0.000109	0.000717	CbGeAlD
Bosutinib—MAP4K5—cerebellum—brain cancer	0.000109	0.000717	CbGeAlD
Bosutinib—CSNK1E—brain—brain cancer	0.000109	0.000715	CbGeAlD
Bosutinib—SRC—head—brain cancer	0.000109	0.000715	CbGeAlD
Bosutinib—SIK1—brain—brain cancer	0.000107	0.000704	CbGeAlD
Bosutinib—IRAK4—brain—brain cancer	0.000107	0.000704	CbGeAlD
Bosutinib—EPHA4—brain—brain cancer	0.000106	0.000697	CbGeAlD
Bosutinib—ERBB3—brain—brain cancer	0.000105	0.00069	CbGeAlD
Bosutinib—MAP2K2—brain—brain cancer	0.000105	0.000688	CbGeAlD
Bosutinib—ULK3—brain—brain cancer	0.000105	0.000688	CbGeAlD
Bosutinib—MAP3K2—brain—brain cancer	0.000104	0.000683	CbGeAlD
Bosutinib—Nausea—Etoposide—brain cancer	0.000104	0.000992	CcSEcCtD
Bosutinib—ABL1—gonad—brain cancer	0.000104	0.00068	CbGeAlD
Bosutinib—YES1—central nervous system—brain cancer	0.000103	0.000678	CbGeAlD
Bosutinib—MAP3K7—brain—brain cancer	0.000103	0.000677	CbGeAlD
Bosutinib—STK10—central nervous system—brain cancer	0.000102	0.000672	CbGeAlD
Bosutinib—TAOK3—central nervous system—brain cancer	0.000102	0.000669	CbGeAlD
Bosutinib—TBK1—brain—brain cancer	0.000102	0.000669	CbGeAlD
Bosutinib—PTK2—brain—brain cancer	0.000102	0.000669	CbGeAlD
Bosutinib—MAP2K5—endocrine gland—brain cancer	0.000101	0.000666	CbGeAlD
Bosutinib—ABL1—pituitary gland—brain cancer	0.000101	0.000663	CbGeAlD
Bosutinib—YES1—cerebellum—brain cancer	0.000101	0.000663	CbGeAlD
Bosutinib—MAP2K5—head—brain cancer	0.0001	0.000657	CbGeAlD
Bosutinib—STK10—cerebellum—brain cancer	0.0001	0.000657	CbGeAlD
Bosutinib—PDGFRB—midbrain—brain cancer	0.0001	0.000656	CbGeAlD
Bosutinib—IRAK1—brain—brain cancer	9.99e-05	0.000656	CbGeAlD
Bosutinib—TAOK3—cerebellum—brain cancer	9.97e-05	0.000654	CbGeAlD
Bosutinib—SRC—central nervous system—brain cancer	9.94e-05	0.000652	CbGeAlD
Bosutinib—CSF1R—endocrine gland—brain cancer	9.9e-05	0.00065	CbGeAlD
Bosutinib—RPS6KB1—brain—brain cancer	9.81e-05	0.000644	CbGeAlD
Bosutinib—CSF1R—head—brain cancer	9.77e-05	0.000641	CbGeAlD
Bosutinib—PDGFRB—spinal cord—brain cancer	9.75e-05	0.00064	CbGeAlD
Bosutinib—ABL1—medulla oblongata—brain cancer	9.75e-05	0.00064	CbGeAlD
Bosutinib—FGR—brain—brain cancer	9.75e-05	0.00064	CbGeAlD
Bosutinib—SRC—cerebellum—brain cancer	9.71e-05	0.000637	CbGeAlD
Bosutinib—AXL—brain—brain cancer	9.71e-05	0.000637	CbGeAlD
Bosutinib—SLK—brain—brain cancer	9.34e-05	0.000613	CbGeAlD
Bosutinib—EPHB4—brain—brain cancer	9.28e-05	0.000609	CbGeAlD
Bosutinib—MAP2K5—central nervous system—brain cancer	9.14e-05	0.0006	CbGeAlD
Bosutinib—EPHA2—brain—brain cancer	9.1e-05	0.000597	CbGeAlD
Bosutinib—FYN—brain—brain cancer	9.09e-05	0.000596	CbGeAlD
Bosutinib—MAP2K5—cerebellum—brain cancer	8.93e-05	0.000586	CbGeAlD
Bosutinib—CSF1R—central nervous system—brain cancer	8.92e-05	0.000586	CbGeAlD
Bosutinib—ABL1—midbrain—brain cancer	8.91e-05	0.000585	CbGeAlD
Bosutinib—MAP4K5—brain—brain cancer	8.88e-05	0.000583	CbGeAlD
Bosutinib—MAP3K3—brain—brain cancer	8.88e-05	0.000583	CbGeAlD
Bosutinib—PDGFRB—endocrine gland—brain cancer	8.78e-05	0.000576	CbGeAlD
Bosutinib—CSF1R—cerebellum—brain cancer	8.72e-05	0.000572	CbGeAlD
Bosutinib—ABL1—spinal cord—brain cancer	8.69e-05	0.000571	CbGeAlD
Bosutinib—PDGFRB—head—brain cancer	8.67e-05	0.000569	CbGeAlD
Bosutinib—YES1—brain—brain cancer	8.2e-05	0.000538	CbGeAlD
Bosutinib—STK10—brain—brain cancer	8.13e-05	0.000533	CbGeAlD
Bosutinib—TAOK3—brain—brain cancer	8.09e-05	0.000531	CbGeAlD
Bosutinib—ABCB1—blood vessel—brain cancer	7.95e-05	0.000522	CbGeAlD
Bosutinib—PDGFRB—central nervous system—brain cancer	7.91e-05	0.000519	CbGeAlD
Bosutinib—SRC—brain—brain cancer	7.89e-05	0.000518	CbGeAlD
Bosutinib—ABL1—endocrine gland—brain cancer	7.82e-05	0.000514	CbGeAlD
Bosutinib—PDGFRB—cerebellum—brain cancer	7.73e-05	0.000508	CbGeAlD
Bosutinib—ABL1—head—brain cancer	7.73e-05	0.000507	CbGeAlD
Bosutinib—MAP2K5—brain—brain cancer	7.26e-05	0.000476	CbGeAlD
Bosutinib—CSF1R—brain—brain cancer	7.08e-05	0.000465	CbGeAlD
Bosutinib—ABL1—central nervous system—brain cancer	7.05e-05	0.000463	CbGeAlD
Bosutinib—ABL1—cerebellum—brain cancer	6.89e-05	0.000452	CbGeAlD
Bosutinib—PDGFRB—brain—brain cancer	6.28e-05	0.000412	CbGeAlD
Bosutinib—ABL1—brain—brain cancer	5.6e-05	0.000367	CbGeAlD
Bosutinib—ABCB1—telencephalon—brain cancer	3.86e-05	0.000253	CbGeAlD
Bosutinib—CYP3A4—endocrine gland—brain cancer	3.44e-05	0.000226	CbGeAlD
Bosutinib—ABCB1—gonad—brain cancer	3.22e-05	0.000211	CbGeAlD
Bosutinib—ABCB1—pituitary gland—brain cancer	3.14e-05	0.000206	CbGeAlD
Bosutinib—CYP3A4—central nervous system—brain cancer	3.1e-05	0.000203	CbGeAlD
Bosutinib—ABCB1—medulla oblongata—brain cancer	3.03e-05	0.000199	CbGeAlD
Bosutinib—ABCB1—midbrain—brain cancer	2.77e-05	0.000182	CbGeAlD
Bosutinib—ABCB1—spinal cord—brain cancer	2.7e-05	0.000177	CbGeAlD
Bosutinib—ABCB1—endocrine gland—brain cancer	2.43e-05	0.00016	CbGeAlD
Bosutinib—ABCB1—head—brain cancer	2.4e-05	0.000158	CbGeAlD
Bosutinib—ABCB1—central nervous system—brain cancer	2.19e-05	0.000144	CbGeAlD
Bosutinib—ABCB1—cerebellum—brain cancer	2.14e-05	0.000141	CbGeAlD
Bosutinib—ABCB1—brain—brain cancer	1.74e-05	0.000114	CbGeAlD
Bosutinib—PTK2—Signaling Pathways—ERBB2—brain cancer	1.85e-06	8.74e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—CTNNB1—brain cancer	1.85e-06	8.7e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CCND1—brain cancer	1.84e-06	8.68e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—RELA—brain cancer	1.84e-06	8.68e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CG—brain cancer	1.84e-06	8.67e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—APC—brain cancer	1.84e-06	8.67e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CTNNB1—brain cancer	1.84e-06	8.66e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—ERBB2—brain cancer	1.83e-06	8.62e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CTNNB1—brain cancer	1.82e-06	8.59e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EGFR—brain cancer	1.82e-06	8.59e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—VEGFA—brain cancer	1.82e-06	8.58e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—APC—brain cancer	1.82e-06	8.58e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—CTNNB1—brain cancer	1.82e-06	8.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CTNNB1—brain cancer	1.81e-06	8.52e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—RELA—brain cancer	1.81e-06	8.51e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—STAT3—brain cancer	1.8e-06	8.5e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SPP1—brain cancer	1.8e-06	8.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—ERBB2—brain cancer	1.79e-06	8.46e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—VEGFA—brain cancer	1.79e-06	8.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CG—brain cancer	1.79e-06	8.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—APC—brain cancer	1.79e-06	8.46e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CTNNB1—brain cancer	1.78e-06	8.41e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BSG—brain cancer	1.78e-06	8.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL2—brain cancer	1.78e-06	8.39e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—STAT3—brain cancer	1.78e-06	8.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CG—brain cancer	1.76e-06	8.28e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—APC—brain cancer	1.76e-06	8.28e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EGFR—brain cancer	1.75e-06	8.26e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—EGFR—brain cancer	1.75e-06	8.25e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—RELA—brain cancer	1.75e-06	8.23e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CTNNB1—brain cancer	1.74e-06	8.2e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—RELA—brain cancer	1.74e-06	8.2e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—ERBB2—brain cancer	1.73e-06	8.18e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CG—brain cancer	1.73e-06	8.15e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—APC—brain cancer	1.73e-06	8.15e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—ERBB2—brain cancer	1.73e-06	8.15e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—VEGFA—brain cancer	1.73e-06	8.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HES1—brain cancer	1.73e-06	8.14e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CG—brain cancer	1.72e-06	8.11e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—APC—brain cancer	1.72e-06	8.11e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—STAT3—brain cancer	1.71e-06	8.07e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—brain cancer	1.7e-06	8.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IRS2—brain cancer	1.69e-06	7.97e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—STAT3—brain cancer	1.68e-06	7.94e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL2—brain cancer	1.68e-06	7.92e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—CTNNB1—brain cancer	1.68e-06	7.91e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MYC—brain cancer	1.67e-06	7.9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—brain cancer	1.67e-06	7.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CTNNB1—brain cancer	1.67e-06	7.87e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—VEGFA—brain cancer	1.66e-06	7.85e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—VEGFA—brain cancer	1.66e-06	7.85e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL2—brain cancer	1.66e-06	7.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—ERBB2—brain cancer	1.66e-06	7.81e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MYC—brain cancer	1.65e-06	7.78e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—STAT3—brain cancer	1.65e-06	7.77e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—STAT3—brain cancer	1.65e-06	7.77e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—RELA—brain cancer	1.64e-06	7.75e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PDGFRA—brain cancer	1.64e-06	7.75e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—STAT3—brain cancer	1.64e-06	7.75e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCND1—brain cancer	1.64e-06	7.72e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—brain cancer	1.64e-06	7.72e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—ERBB2—brain cancer	1.63e-06	7.7e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IRS2—brain cancer	1.63e-06	7.68e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL2—brain cancer	1.63e-06	7.67e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CTNNB1—brain cancer	1.62e-06	7.65e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCND1—brain cancer	1.62e-06	7.62e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—brain cancer	1.61e-06	7.61e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—STAT3—brain cancer	1.61e-06	7.58e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—VEGFA—brain cancer	1.6e-06	7.57e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—STAT3—brain cancer	1.6e-06	7.55e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CTNNB1—brain cancer	1.6e-06	7.54e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—ERBB2—brain cancer	1.6e-06	7.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SPP1—brain cancer	1.6e-06	7.52e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—brain cancer	1.59e-06	7.5e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MYC—brain cancer	1.59e-06	7.5e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—STAT3—brain cancer	1.59e-06	7.49e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—STAT3—brain cancer	1.58e-06	7.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—STAT3—brain cancer	1.58e-06	7.43e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL2—brain cancer	1.57e-06	7.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CTNNB1—brain cancer	1.57e-06	7.4e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—brain cancer	1.57e-06	7.39e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL2—brain cancer	1.57e-06	7.39e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—brain cancer	1.56e-06	7.33e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—STAT3—brain cancer	1.55e-06	7.33e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—RELA—brain cancer	1.54e-06	7.26e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCND1—brain cancer	1.53e-06	7.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—IDH1—brain cancer	1.53e-06	7.22e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MYC—brain cancer	1.53e-06	7.22e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MYC—brain cancer	1.53e-06	7.22e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—ERBB2—brain cancer	1.53e-06	7.22e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—brain cancer	1.53e-06	7.21e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CTNNB1—brain cancer	1.52e-06	7.16e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—STAT3—brain cancer	1.52e-06	7.15e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—CTNNB1—brain cancer	1.51e-06	7.13e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—brain cancer	1.5e-06	7.06e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—brain cancer	1.5e-06	7.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—APC—brain cancer	1.49e-06	7.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CG—brain cancer	1.49e-06	7.04e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—brain cancer	1.49e-06	7.04e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—brain cancer	1.48e-06	6.98e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—brain cancer	1.48e-06	6.96e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—STAT3—brain cancer	1.46e-06	6.89e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—brain cancer	1.46e-06	6.89e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—brain cancer	1.46e-06	6.86e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—STAT3—brain cancer	1.45e-06	6.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—CTNNB1—brain cancer	1.45e-06	6.83e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—brain cancer	1.44e-06	6.81e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—brain cancer	1.44e-06	6.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS2—brain cancer	1.44e-06	6.8e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCND1—brain cancer	1.44e-06	6.8e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—APC—brain cancer	1.44e-06	6.79e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CG—brain cancer	1.44e-06	6.79e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—brain cancer	1.44e-06	6.79e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—RELA—brain cancer	1.44e-06	6.77e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—brain cancer	1.43e-06	6.75e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CTNNB1—brain cancer	1.43e-06	6.74e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VEGFA—brain cancer	1.43e-06	6.73e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ERBB2—brain cancer	1.43e-06	6.73e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—STAT3—brain cancer	1.41e-06	6.67e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—ERBB2—brain cancer	1.41e-06	6.66e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—brain cancer	1.41e-06	6.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—brain cancer	1.41e-06	6.65e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VEGFA—brain cancer	1.41e-06	6.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—RELA—brain cancer	1.4e-06	6.61e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CTNNB1—brain cancer	1.4e-06	6.58e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—STAT3—brain cancer	1.39e-06	6.58e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ERBB2—brain cancer	1.39e-06	6.57e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—brain cancer	1.39e-06	6.54e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—brain cancer	1.38e-06	6.5e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—brain cancer	1.38e-06	6.48e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—RELA—brain cancer	1.37e-06	6.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—STAT3—brain cancer	1.37e-06	6.45e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—brain cancer	1.36e-06	6.43e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—brain cancer	1.36e-06	6.41e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—brain cancer	1.36e-06	6.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—brain cancer	1.35e-06	6.37e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—RELA—brain cancer	1.35e-06	6.37e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RELA—brain cancer	1.34e-06	6.34e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—brain cancer	1.34e-06	6.33e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTNNB1—brain cancer	1.34e-06	6.31e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—brain cancer	1.34e-06	6.3e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—brain cancer	1.34e-06	6.3e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—brain cancer	1.33e-06	6.27e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—STAT3—brain cancer	1.32e-06	6.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—brain cancer	1.32e-06	6.23e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—STAT3—brain cancer	1.32e-06	6.22e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—brain cancer	1.31e-06	6.2e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—brain cancer	1.31e-06	6.16e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—brain cancer	1.3e-06	6.11e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—brain cancer	1.29e-06	6.1e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—brain cancer	1.29e-06	6.06e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CG—brain cancer	1.27e-06	6.01e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—APC—brain cancer	1.27e-06	6.01e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—brain cancer	1.27e-06	5.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—STAT3—brain cancer	1.26e-06	5.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—brain cancer	1.26e-06	5.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—brain cancer	1.26e-06	5.95e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—brain cancer	1.26e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—brain cancer	1.26e-06	5.93e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—brain cancer	1.26e-06	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CTNNB1—brain cancer	1.25e-06	5.89e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—STAT3—brain cancer	1.25e-06	5.87e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CTNNB1—brain cancer	1.24e-06	5.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—brain cancer	1.24e-06	5.83e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—brain cancer	1.23e-06	5.8e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—brain cancer	1.23e-06	5.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CTNNB1—brain cancer	1.22e-06	5.75e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—STAT3—brain cancer	1.22e-06	5.74e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—brain cancer	1.22e-06	5.74e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—brain cancer	1.21e-06	5.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—brain cancer	1.21e-06	5.71e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—brain cancer	1.21e-06	5.71e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—brain cancer	1.2e-06	5.68e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—brain cancer	1.2e-06	5.67e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—brain cancer	1.2e-06	5.65e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—brain cancer	1.19e-06	5.63e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—brain cancer	1.19e-06	5.59e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—brain cancer	1.18e-06	5.56e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—brain cancer	1.17e-06	5.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—brain cancer	1.17e-06	5.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—brain cancer	1.17e-06	5.51e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—brain cancer	1.17e-06	5.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RELA—brain cancer	1.17e-06	5.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—brain cancer	1.16e-06	5.47e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—brain cancer	1.16e-06	5.46e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—brain cancer	1.13e-06	5.34e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—brain cancer	1.13e-06	5.33e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RELA—brain cancer	1.12e-06	5.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—brain cancer	1.12e-06	5.27e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—brain cancer	1.11e-06	5.22e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—brain cancer	1.1e-06	5.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—brain cancer	1.09e-06	5.13e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—brain cancer	1.08e-06	5.09e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—brain cancer	1.08e-06	5.08e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—brain cancer	1.07e-06	5.06e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—brain cancer	1.06e-06	5.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—brain cancer	1.06e-06	5.01e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—brain cancer	1.06e-06	5e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—brain cancer	1.05e-06	4.96e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—brain cancer	1.05e-06	4.95e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—brain cancer	1.04e-06	4.9e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—brain cancer	1.03e-06	4.88e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—brain cancer	1.03e-06	4.85e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—brain cancer	1.02e-06	4.83e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—brain cancer	1.02e-06	4.83e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—brain cancer	1.02e-06	4.8e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—brain cancer	1.01e-06	4.78e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—brain cancer	1.01e-06	4.78e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—brain cancer	1.01e-06	4.77e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—brain cancer	1.01e-06	4.76e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—brain cancer	1e-06	4.72e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RELA—brain cancer	9.96e-07	4.69e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—brain cancer	9.89e-07	4.67e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—brain cancer	9.89e-07	4.66e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—brain cancer	9.88e-07	4.66e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—brain cancer	9.87e-07	4.65e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—brain cancer	9.79e-07	4.62e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—brain cancer	9.78e-07	4.61e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—brain cancer	9.66e-07	4.56e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—brain cancer	9.65e-07	4.55e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—brain cancer	9.51e-07	4.49e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—brain cancer	9.5e-07	4.48e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—brain cancer	9.46e-07	4.46e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—brain cancer	9.45e-07	4.46e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—brain cancer	9.31e-07	4.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—brain cancer	9.26e-07	4.36e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CG—brain cancer	9.02e-07	4.25e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—brain cancer	8.97e-07	4.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—brain cancer	8.93e-07	4.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—brain cancer	8.85e-07	4.17e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—brain cancer	8.74e-07	4.12e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—brain cancer	8.66e-07	4.08e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—brain cancer	8.61e-07	4.06e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—brain cancer	8.52e-07	4.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—brain cancer	8.31e-07	3.92e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—brain cancer	8.22e-07	3.88e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—brain cancer	8.11e-07	3.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—brain cancer	7.94e-07	3.74e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—brain cancer	7.92e-07	3.73e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—brain cancer	7.81e-07	3.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—brain cancer	7.77e-07	3.66e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—brain cancer	7.75e-07	3.65e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—brain cancer	7.62e-07	3.59e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—brain cancer	7.55e-07	3.56e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—brain cancer	7.01e-07	3.31e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—brain cancer	6.86e-07	3.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—brain cancer	6.75e-07	3.18e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—brain cancer	6.5e-07	3.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—brain cancer	5.76e-07	2.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CG—brain cancer	5.56e-07	2.62e-06	CbGpPWpGaD
